Privia Health Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Privia Health Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.92M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $14.39M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $23.08M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($8.59M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($188.23M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $31.24M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $8.24M | Mar 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.24M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $16.98M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $20.65M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($19.12M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($217.44M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $25.38M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $16.06M | Mar 25, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.40M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $109.28M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $80.79M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $47.20M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $55.06M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $38.89M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $24.36M | Mar 25, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $113.0K | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | $104.0K | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $547.0K | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $380.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $5.71M | Mar 25, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.37B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.14B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $999.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $792.81M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $686.37M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $328.97M | Mar 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $578.44M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $452.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $392.51M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $273.76M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $236.19M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $185.32M | Mar 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $737.22M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $635.18M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $561.44M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $499.09M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $426.87M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $146.75M | Mar 25, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.84M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $141.62M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $138.75M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $126.94M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $127.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $118.66M | Mar 25, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($156.31M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($179.23M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($193.61M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($216.69M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($208.11M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($19.88M) | Mar 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $479.69M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $491.15M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $389.51M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $347.99M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $320.58M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $84.63M | Mar 25, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 123.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 120.31M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 118.22M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 114.69M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 107.84M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 95.99M | Mar 25, 2022 |